# Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

> **NCT04953962** · PHASE2 · COMPLETED · sponsor: **CanBas Co. Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Pancreatic Cancer Stage IV

## Interventions

- **DRUG:** CBP501 (16)
- **DRUG:** CBP501 (25)
- **DRUG:** Cisplatin
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04953962
- **Lead sponsor:** CanBas Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-18
- **Primary completion:** 2023-04-14
- **Final completion:** 2023-04-14
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04953962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04953962, "Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04953962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*